

## Randomised Data from the SOLVE-CRT Trial to be Presented at 16<sup>th</sup> APHRS Scientific Session

**Sunnyvale, California; 11 August 2023:** EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to announce that additional clinical data from the Company’s pivotal SOLVE-CRT (“SOLVE”) trial will be featured at the 16<sup>th</sup> Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in Hong Kong from the 1<sup>st</sup> to the 3<sup>rd</sup> of September.

The APHRS is a leading non-profit organisation that represents medical, allied health, and science professionals specialising in cardiac rhythm disorders in the Asia-Pacific region. The annual conference is a premier event featuring industry workshops and a core scientific programme delivered by international and regional speakers. EBR’s participation in leading conferences such as APHRS is important to strengthen the body of supporting clinical data and promote the Company’s WiSE® CRT System amongst a wide audience including key members of the scientific and clinical community.

The Late Breaking Clinical Trial presentation will share outcomes from the randomised arm of the SOLVE trial. A total of 108 participants were enrolled in the randomised part of SOLVE. All participants underwent device implant and were then randomised in a 1:1 ratio to treatment (System ON) or control (System OFF) groups. The clinical outcomes from this randomised cohort will build on the positive results achieved in the single arm part of the SOLVE-CRT trial, as announced in May this year:

*Leadless Ultrasound-Based Cardiac Resynchronization Pacing System in Heart Failure – Randomized Efficacy Results in Non-responder, Previously-untreatable and High-risk CRT Upgrades from the SOLVE-CRT Study* – presented by Professor Prashanthan Sanders (Royal Adelaide Hospital, AU).

This abstract was submitted without any outcomes as the data was still being analysed ahead of the submission date. EBR’s presentation is scheduled for Saturday, 2<sup>nd</sup> September in late-breaking session 3 from 4:00 to 5:40 PM HKT. EBR will make an ASX announcement on this new clinical data following the presentation, after lifting of the embargo.

A second abstract was also accepted for presentation, which will support additional clinical utilisation of EBR’s WiSE CRT System:

- *Electro-anatomical characterisation of leadless cardiac resynchronisation therapy* – presented by Dr Nadeev Wijesuriya (King’s College London, UK)

**John McCutcheon, EBR Systems’ President & Chief Executive Officer said:**

*“We are excited to see our pioneering WiSE CRT System continue to feature at leading global conferences. The abstracts presented at this scientific session strengthen the body of data supporting WiSE while promoting our technology to a wide audience including industry partners and the broader scientific community.”*

**ENDS**

***This announcement has been authorised for release by the EBR Systems General Disclosure Committee, a committee of the Board of Directors.***

**For more information, please contact:**

**Company**

Frank Hettmann  
Chief Financial Officer  
P: +1 408 720 1906  
E: [info@ebrsystemsinc.com](mailto:info@ebrsystemsinc.com)

**Investors**

Dean Dribbin  
Vesparum Capital  
P: +61 3 8582 4800  
E: [EBRSystems@vesparum.com](mailto:EBRSystems@vesparum.com)

**About EBR Systems (ASX: EBR)**

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

**EBR Systems' WiSE® Technology**

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

**Foreign Ownership Restriction**

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

